Latest Headlines
Stereotactic radiation controls early stage lung cancer
Melanoma survivors at higher risk of other cancers
Cladribine and fludarabine equally helpful for progressive CLL
More frequent surveillance reduces colon cancer risk in Lynch syndrome families
Radiation can be avoided in early Hodgkin's lymphoma
NEWS PROVIDED BY 
VIEW ALL NEWSFDA advisers back Glaxo, Genmab cancer drug
ORLANDO, Florida (Reuters) - A small trial of Arzerra, being developed by GlaxoSmithKline Plc and Genmab for treating chronic lymphocytic leukemia, indicated benefits sufficient for U.S. approval, an advisory committee to regulators said on Friday.
The panel voted 10-3 that the trial results were likely to predict clinical benefit in patients with CLL, a common type of blood cancer in adults. One member abstained from the voting.
"I am impressed by the resolution of symptoms," said Dr. Margaret Tempero, deputy director at the University of California at San Francisco's cancer center and a member of the advisory committee. "I also thought the overall survival benefit looked encouraging."
Glaxo and Genmab are seeking accelerated approval of Arzerra, based on results from a small trial that did not include a comparison arm.
Much of the discussion at the panel hearing centered on whether new criteria requiring that tumors be measured with CT scans should be applied to the Arzerra trial.
A clinical trial showed a 58 percent response rate to Arzerra in patients who failed the two prior chemotherapy regimens, a higher level than the normal 25 percent level, Glaxo spokeswoman Lisa Behrens said.
The median duration of response for patients in the trial was 6.5 months.
Infections, including fatal ones, were seen frequently in the study but it was not possible to determine how much infection risk was due to the drug, FDA staff said. Heavily treated CLL patients normally have high infection rates.
Glaxo officials said two larger phase III trials of Arzerra are being launched, but it will be roughly five years before those results are available.
Copyright © 2009 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.
NEWS PROVIDED BY
TEXT SIZE 